ClinicalTrials.gg
CompletedNCT06729905INFU-SALUDUpdated May 22, 2025

Study of the Effects of Yerba Mate on Cardiometabolic Health

An interventional study of Yerba mate tea and Control drink in Cardiovascular Risk and Hypercholerolemia, sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición. Completed at 1 site in Spain. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 12 years 10 months after the study started (first participant enrolled Jan 2012, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Inflammation with a site in Spain — 32 open to participants now, 41 under way, 2 of them phase 3. Inflammation · Spain.

Enrollment
75th of 114
52 · median 68
Started
2012
with 9 others
No phase
71 of 149
17 open now
Registered
119th of 149
by date

Among the 149 studies in Inflammation with a site in Spain, this one is the 75th largest by enrollment of the 114 interventional ones that give a count, is one of 10 that started in 2012, is one of 71 with no phase, and was the 119th registered.

Inflammation

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

Browse Inflammation studies →

Open to participants now

32 of the 149 studies in Inflammation with a site in Spain are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Inflammation with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if consuming a beverage prepared with yerba mate leaves helps to improve blood lipid levels in persons at high cardiovascular risk. It will also learn about the effects of this beverage, widely consumed in South America, on other cardiometabolic biomarkers like blood glucose levels, inflammation, or weight control. The main questions it aims to answer are:

Does daily consumption of a yerba mate tea reduce the blood lipid levels in hypercholesterolemic persons? May healthy persons also benefit from the consumption of yerba mate tea?

Researchers will compare yerba mate to a control drink (isotonic drink or water, free of polyphenols and caffeine) to see if yerba mate tea helps to reduce blood cholesterol in hypercholesterolemic persons.

Participants will:

Drink 3 cups of yerba mate tea or an isotonic drink every day for 2 months, then change to the other drink during another 2 months.

Visit the clinic at the beginning and end of each 2-month period for checkups and tests Refraing from consuming coffee and some foods during the study. Complete a dietary questionnaire during 3 days before each visit to the clinic.

Read the detailed description

This is a randomized, crossover, control study in healthy and hypercholesterolemic free-living to assess the effect of yerba mate on different outcomes related to cardiovascular health.

After a 2-week run-in period, participants will be randomly allocated to the first 8-weeks intervention with yerba mate or the control drink. After a 3-week wash-out, they will change to consume during 8 weeks the other drink.

A nurse will collect a fasting blood sample at the beginning and end of each intervention stage. Blood pressure and anthropometric parameters will be measured. A 72-h dietary record will be completed by participants before each visit to the Human Nutrition Unit (HNU) at the Institute of Food Science, Technology and Nutrition (ICTAN-CSIC).

During the study, participants will refrain from consuming coffee, cocoa, tea, and caffeine-containing drinks. Other foods rich in certain polyphenols (i.e. hydroxycinnamic acids) will also be restricted.

Blood samples will be used to measure different biomarkers of relevance in cardiometabolic health, as listed in the Outcomes section.

03

Conditions studied

  • Cardiovascular Risk
  • Hypercholerolemia

Browse trials for

Keywords

  • Yerba mate
  • Cardiovascular health
  • Inflammation
  • Blood lipids
  • Glucose homeostasis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 20-25 kg/m2
  • Total cholesterol \< 200 mg/dL for healthy participants, between 200-240 mg/dL for participants at cardiovascular risk, or
  • LDL cholesterol \< 130 mg/dL for healthy participants, between 130-159 mg/dL for participants at cardiovascular risk.

Exclusion criteria

Exclusion Criteria:

  • Smoking
  • Pregnant/lactating women
  • Vegetarians/vegans
  • Consumption of vitamins or dietary supplements
  • Suffering from chronic diseases/pathologies/conditions appart from hypercholesterolemia
  • On prescription drugs (statins) or on antibiotics 6 months before the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Yerba mate

    Consumption of three cups of a yerba mate tea per day

    Dietary Supplement: Yerba mate tea

  • Other
    Control

    Consuming water or an isotonic drink, free of polyphenols or caffeine.

    Dietary Supplement: Control drink

Interventions

  • Dietary supplementYerba mate tea

    Consumption of three cups per day of a beverage prepared with yerba mate

  • Dietary supplementControl drink

    Consumption of water or an isotonic drink, free of polyphenols or caffeine. Abstention of consuming coffee.

06

What researchers measure

Primary outcomes

  1. Blood lipids

    Change in blood levels of total cholesterol or LDL-cholesterol or VLDL-cholesterol or HDL-cholesterol or triglycerides or phospholipids at the end of the intervention with yerba mate

    Time frame: From enrollment to the end of each treatment at 8 weeks

Secondary outcomes

  1. Blood pressure

    Changes in blood pressure at the end of the intervention with yerba mate.

    Time frame: From enrollment to the end of each treatment at 8 weeks

  2. Inflammatory cytokines

    Change in the levels of C-reactive protein (CRP), or pro-inflammatory cytokines (tumor necrosis factor-alpha (TNF-a), or interferon gamma (IFN-g), interleukin (IL)-1beta (IL-1b), or IL-2, or IL-5, or IL-6, or IL-7, or IL-8, or IL-12 or IL-13)) or anti-inflammatory cytokines IL-4 or IL-10 at the end of the intervention with yerba mate

    Time frame: From enrollment to the end of each treatment at 8 weeks

  3. Fasting blood glucose

    Change of fasting blood glucose levels at the end of the intervention with yerba mate

    Time frame: From enrollment to the end of each treatment at 8 weeks

  4. Fasting blood insulin

    Change of fasting insulin levels at the end of intervention with yerba mate

    Time frame: From enrollment to the end of each treatment at 8 weeks

  5. Insulin resistance

    Change in homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) at the end of intervention with yerba mate

    Time frame: From enrollment to the end of each treatment at 8 weeks

  6. Insulin sensitivity

    Change in quantitative insulin levels sensitivity check index (QUICKI) at the end of the intervention with yerba mate. Higher score in QUICKI means a better outcome compared to initial values.

    Time frame: From enrollment to the end of each treatment at 8 weeks

  7. Hormones, incretins and adipokines levels

    Changes in serum levels of C peptide or glucagon or glucagon inhibitory peptide (GIP) or glucagon-like peptide type 1 (GLP-1) or ghrelin or leptin or resistin or plasminogen activator inhibitor type 1 (PAI-1) or visfatin at the end of the intervention with yerba mate.

    Time frame: From enrollment to the end of each treatment at 8 weeks

  8. Cytokines, chemokines and cell-adherence molecules levels

    Changes in serum levels of granulocyte (G-CSF) or granulocyte/macrophague (GM-CSF) colony-stimulating factors, or monocyte-chemoattractant protein-1 (MCP-1) or macrophage inflammatory protein-1beta (MIP-1b) or vascular (VCAM-1) or intracellular (ICAM-1) adhesion molecules at the end of the intervention with yerba mate.

    Time frame: From enrollment to the end of each treatment at 8 weeks

  9. Liver function

    No changes in serum levels of alanin transferase (ALAT), or aspartate transferase (ASAT) at the end of the intervention with yerba mate.

    Time frame: From enrollment to the end of each treatment at 8 weeks

  10. Anthropometry

    Changes in body weight or body fat percentage or body circunferences (wais, or hip, or thigh, or brachial) or skinfolds (tricipital or subscapular) at the end of the intervention with yerba mate.

    Time frame: From enrollment to the end of each treatment at 8 weeks

07

Study locations

1 site
  • Instituto de Ciencia y Tecnología de Alimentos y Nutrición
    Madrid, 28040, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Jul 2013, 18 months.

Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 18 months is close to that.

Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2024
First posted
Dec 12, 2024
StartActual
Jan 10, 2012
Primary completionActual
Jul 30, 2013
CompletionActual
May 30, 2015
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06729905
Lead sponsor
Instituto de Ciencia y Tecnología de Alimentos y Nutrición
Collaborators
Ministry of Science and Innovation, Spain
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Jan 10, 2012
Primary completion
Jul 30, 2013
Completion
May 30, 2015
Last update
May 22, 2025

Study contacts

Laura Bravo, Professor
principal investigator · ICTAN-CSIC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion